

Valeant announces 2018 Annual Meeting Results

May 01, 2018

LAVAL, QUEBEC, May 1, 2018 - Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today the election of the ten directors nominated at its 2018 annual meeting of shareholders held on April 30, 2018. The detailed results of the vote for the election of directors are set out below:

Name	For	Withheld	Broker Non-Votes
Richard U. DeSchutter	122,436,178	3,773,166	119,704,902
D. Robert Hale	122,525,860	3,683,484	119,704,902
Dr. Argeris (Jerry) N. Karabelas	122,263,489	3,945,855	119,704,902
Sarah B. Kavanagh	124,267,683	1,941,661	119,704,902
Joseph C. Papa	122,891,673	3,317,671	119,704,902
John A. Paulson	124,845,242	1,364,102	119,704,902
Robert N. Power	121,924,191	4,285,153	119,704,902
Russel C. Robertson	124,506,915	1,702,429	119,704,902
Thomas W. Ross, Sr.	123,823,094	2,386,250	119,704,902
Amy B. Wechsler, M.D.	122,368,488	3,840,856	119,704,902

At the annual meeting, shareholders also approved the non-binding advisory vote on named executive officer compensation and an amendment to the Company's 2014 Omnibus Incentive Plan to increase the number of common shares authorized under such plan, and appointed PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the Company's 2019 annual meeting of shareholders.

The final vote tabulation on all matters voted on at the meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K and such report will be made available on the Company's web site at

www.valeant.com

.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.

Investor Contact:

Arthur Shannon

arthur.shannon@valeant.com

(514) 856-3855

(877) 281-6642 (toll free)

Media Contact:

Lainie Keller

lainie.keller@valeant.com

(908) 927-0617

###



Investor Inquiries

ir@bauschhealth.com

877-281-6642

514-856-3855 (Canada)

Media inquiries

Corporate.communications@bauschhealth.com

908-569-3692

[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.

©2025 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION